Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes.

BACKGROUND Smoking has carcinogenic effects, and possibly antiestrogenic effects as well, but it has not been found to be a risk factor for breast cancer in women in the general population. However, hereditary breast cancer is primarily a disease of premenopausal women, and interactions between genes and hormonal and environmental risk factors may be particularly important in this subgroup. METHODS We conducted a matched case-control study of breast cancer among women who have been identified to be carriers of a deleterious mutation in either the BRCA1 or the BRCA2 gene. These women were assessed for genetic risk at one of several genetic counseling programs for cancer in North America. Information about lifetime smoking history was derived from a questionnaire routinely administered to women who were found to carry a mutation in either gene. Smoking histories of case subjects with breast cancer and age-matched healthy control subjects were compared. Odds ratios for developing breast cancer were determined for smokers versus nonsmokers by use of conditional logistic regression for matched sets after adjustment for other known risk factors. RESULTS Subjects with BRCA1 or BRCA2 gene mutations and breast cancer were significantly more likely to have been nonsmokers than were subjects with mutations and without breast cancer (two-sided P = .007). In a multivariate analysis, subjects with BRCA1 or BRCA2 mutations who had smoked cigarettes for more than 4 pack-years (i.e., number of packs per day multiplied by the number of years of smoking) were found to have a lower breast cancer risk (odds ratio = 0.46, 95% confidence interval = 0.27-0.80; two-sided P = .006) than subjects with mutations who never smoked. CONCLUSIONS This study raises the possibility that smoking reduces the risk of breast cancer in carriers of BRCA1 or BRCA2 gene mutations.

[1]  C. Labrie,et al.  Almost Exclusive Androgenic Action of Dehydroepiandrosterone in the Rat Mammary Gland. , 1998, Endocrinology.

[2]  J. Holtzman,et al.  Correspondence re: G. C. Kabat et al., Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol., Biomark. Prev., 6: 505-509, 1997. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[3]  J. Goméz,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Effect of 12-Month Dehydroepiandrosterone Replacement Therapy on Bone, Vagina, and Endometrium in Postmenopausal Women , 2022 .

[4]  J. Simard,et al.  Characterization of the effects of the novel non‐steroidal antiestrogen EM‐800 on basal and estrogen‐induced proliferation of T‐47D, ZR‐75‐1 and MCF‐7 human breast cancer cells in vitro , 1997, International journal of cancer.

[5]  C. Labrie,et al.  Effect of Dehydroepiandrosterone on Bone Mass, Serum Lipids, and Dimethylbenz(a)anthracene-Induced Mammary Carcinoma in the Rat. , 1997, Endocrinology.

[6]  J. Simard,et al.  (S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen. , 1997, Journal of medicinal chemistry.

[7]  J. Sparano,et al.  Urinary estrogen metabolites and breast cancer: a case-control study. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[8]  P. Hartge,et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[9]  F. Speizer,et al.  Birthweight as a risk factor for breast cancer , 1997 .

[10]  D. Kiel,et al.  Bone mass and the risk of breast cancer among postmenopausal women. , 1997, The New England journal of medicine.

[11]  D. Zaridze,et al.  Genetic polymorphisms and breast cancer risk. , 1997, Journal of the American Medical Association (JAMA).

[12]  J. Robins,et al.  Birthweight as risk factor for breast cancer , 1997, The Lancet.

[13]  B. Stall Brithweight as risk factor for breast cancer , 1997, The Lancet.

[14]  J. Robins,et al.  Birthweight as risk factor for breast cancer (multiple letters) [1] , 1997 .

[15]  J. Robins,et al.  BIRTHWEIGHT AS RISK FACTOR FOR BREAST CANCER. AUTHORS' REPLY , 1997 .

[16]  S. Seal,et al.  Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene , 1997, Nature Genetics.

[17]  J. Freudenheim,et al.  Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. , 1996, JAMA.

[18]  B Fisher,et al.  Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. , 1996, Journal of the National Cancer Institute.

[19]  C. Labrie,et al.  High bioavailability of dehydroepiandrosterone administered percutaneously in the rat. , 1996, The Journal of endocrinology.

[20]  B. Trock,et al.  BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. , 1996, JAMA.

[21]  J. Simard,et al.  The 3β-Hydroxysteroid Dehydrogenase/Isomerase Gene Family: Lessons from Type II 3β-HSD Congenital Deficiency , 1996 .

[22]  L. Cannon-Albright,et al.  Risk modifiers in carriers of brca1 mutations , 1995, International journal of cancer.

[23]  J. Simard,et al.  DHEA and Peripheral Androgen and Estrogen Formation: Intracrinology , 1995, Annals of the New York Academy of Sciences.

[24]  P. Tonin,et al.  A large multisite cancer family is linked to BRCA2. , 1995, Journal of medical genetics.

[25]  V. Jordan,et al.  Hormonal treatment of advanced breast cancer. , 1995, Surgical oncology clinics of North America.

[26]  S. Hilsenbeck,et al.  Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. , 1995, Journal of the National Cancer Institute.

[27]  D. Easton,et al.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.

[28]  B. Bengtsson,et al.  Serum insulin‐like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin , 1994, Clinical endocrinology.

[29]  M. Thun,et al.  Cigarette smoking and risk of fatal breast cancer. , 1994, American journal of epidemiology.

[30]  N. Skakkebaek,et al.  Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. , 1994, The Journal of clinical endocrinology and metabolism.

[31]  J. Bringer,et al.  Androgen receptor gene mutation in male breast cancer. , 1993, Human molecular genetics.

[32]  E. Thomas,et al.  The impact of cigarette smoking on the plasma concentrations of gonadotrophins, ovarian steroids and androgens and upon the metabolism of oestrogens in the human female. , 1993, Human reproduction.

[33]  A. Ashworth,et al.  Control of aromatase in breast cancer cells and its importance for tumor growth , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[34]  J. Bonneterre,et al.  Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. , 1993, European journal of cancer.

[35]  M. Stratton,et al.  A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome , 1992, Nature Genetics.

[36]  A. Wakeling,et al.  ICI 182,780, a new antioestrogen with clinical potential , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[37]  R. Frairia,et al.  Smoking effects on the hormonal balance of fertile women. , 1992, Hormone research.

[38]  C. Osborne,et al.  Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. , 1991, Journal of the National Cancer Institute.

[39]  K. Schulz,et al.  Androgen sensitivity of the new human breast cancer cell line MFM-223. , 1991, Cancer research.

[40]  F. Labrie,et al.  Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice. , 1991, Cancer research.

[41]  D. Schaid,et al.  Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis , 1991, Cancer.

[42]  C. la Vecchia,et al.  The antiestrogenic effect of cigarette smoking in women. , 1990, American journal of obstetrics and gynecology.

[43]  J. Simard,et al.  Regulation of progesterone-binding breast cyst protein GCDFP-24 secretion by estrogens and androgens in human breast cancer cells: a new marker of steroid action in breast cancer. , 1990, Endocrinology.

[44]  B. Rimer,et al.  The Older Smoker: Status, Challenges and Opportunities for Intervention , 1990 .

[45]  V. Jordan,et al.  Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. , 1989, Cancer research.

[46]  F. Labrie,et al.  Additive inhibitory effects of bromocryptine (CB-154) and medroxyprogesterone acetate (MPA) on dimethylbenz[a]anthracene (DMBA)-induced mammary tumors in the rat. , 1989, European journal of cancer & clinical oncology.

[47]  J. Simard,et al.  Inhibitory effect of estrogens on GCDFP-15 mRNA levels and secretion in ZR-75-1 human breast cancer cells. , 1989, Molecular endocrinology.

[48]  J. Baron,et al.  Cigarette smoking and breast cancer. , 1989, American journal of epidemiology.

[49]  N. Davidson,et al.  The role of estrogens in growth regulation of breast cancer. , 1989, Critical reviews in oncogenesis.

[50]  M. Dumont,et al.  Antagonism between estrogens and androgens on GCDFP-15 gene expression in ZR-75-1 cells and correlation between GCDFP-15 and estrogen as well as progesterone receptor expression in human breast cancer. , 1989, Journal of steroid biochemistry.

[51]  C. Labrie,et al.  Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. , 1988, Endocrinology.

[52]  S. Robinson,et al.  Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. , 1988, Cancer research.

[53]  C. Osborne,et al.  Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. , 1987, European journal of cancer & clinical oncology.

[54]  C. la Vecchia,et al.  Cigarette smoking and the risk of endometrial cancer. , 1987, European journal of cancer & clinical oncology.

[55]  H. Bradlow,et al.  Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. , 1986, The New England journal of medicine.

[56]  F. Labrie,et al.  Stimulation of cell proliferation and estrogenic response by adrenal C19-delta 5-steroids in the ZR-75-1 human breast cancer cell line. , 1986, Cancer research.

[57]  C. Christiansen,et al.  Cigarette smoking, serum estrogens, and bone loss during hormone-replacement therapy early after menopause. , 1985, The New England journal of medicine.

[58]  W. Miller,et al.  Androgen receptor activity in human breast cancer and its relationship with oestrogen and progestogen receptor activity. , 1985, European journal of cancer & clinical oncology.

[59]  R. Bryan,et al.  Androgen receptors in breast cancer , 1984, Cancer.

[60]  V. Jordan,et al.  Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: Problems and potential for future clinical applications , 1983, Breast cancer research and treatment.

[61]  B. Edwards,et al.  Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. , 1983, Annals of internal medicine.

[62]  N. Weiss,et al.  Effect of Weight, Smoking, and Estrogen Use on the Risk of Hip and Forearm Fractures in Postmenopausal Women , 1982, Obstetrics and gynecology.

[63]  B. Macmahon,et al.  Cigarette smoking and urinary estrogens. , 1982, The New England journal of medicine.

[64]  A. Bélanger,et al.  Characteristics of binding to estrogen, androgen, progestin, and glucocorticoid receptors in 7,12-dimethylbenz(a)anthracene-induced mammary tumors and their hormonal control. , 1980, Cancer research.

[65]  G. Hortobagyi,et al.  Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. , 1979, Cancer research.

[66]  A. Schwartz Inhibition of spontaneous breast cancer formation in female C3H(Avy/a) mice by long-term treatment with dehydroepiandrosterone. , 1979, Cancer research.

[67]  F. Labrie,et al.  Effects of estradiol and prolactin on steroid receptor levels in 7,12-dimethylbenz(a)anthracene-induced mammary tumors and uterus in the rat. , 1978, Journal of steroid biochemistry.

[68]  P. Kelly,et al.  Inhibitory Effect of LHRH and Its Agonists on Testicular Gonadotrophin Receptors and Spermatogenesis in the Rat , 1978 .

[69]  M. Caron,et al.  Control of hormone receptor levels and growth of 7,12-dimethylbenz(a)anthracene-induced mammary tumors by estrogens, progesterone and prolactin. , 1977, Endocrinology.

[70]  A. Segaloff The use of androgens in the treatment of neoplastic disease , 1977 .

[71]  G. Trams,et al.  Specific binding of estradiol and dihydrotestosterone in human mammary cancers. , 1977, Cancer research.

[72]  J. Meites,et al.  Counteraction by prolactin of androgen-induced inhibition of mammary tumor growth in rats. , 1974, Journal of the National Cancer Institute.

[73]  A. Segaloff,et al.  Hormonal therapy in cancer of the breast. I. The effect of testosterone propionate therapy on clinical course and hormonal excretion , 1951, Cancer.